Journal of Diagnostics Concepts & Practice ›› 2019, Vol. 18 ›› Issue (04): 387-393.doi: 10.16150/j.1671-2870.2019.04.003
• Academic trends at home and abroad • Previous Articles Next Articles
Received:2019-05-10
Online:2019-08-25
Published:2019-08-25
CLC Number:
| [1] |
Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy[J]. Clin Cancer Res, 2015, 21(4):687-692.
doi: 10.1158/1078-0432.CCR-14-1860 URL |
| [2] |
Allard B, Aspeslagh S, Garaud S, et al. Immuno-oncology-101: overview of major concepts and translational perspectives[J]. Semin Cancer Biol, 2018, 52(Pt 2):1-11.
doi: S1044-579X(17)30233-X pmid: 29428479 |
| [3] |
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point[J]. Nature, 2017, 541(7637):321-330.
doi: 10.1038/nature21349 URL |
| [4] | Sambi M, Bagheri L, Szewczuk MR. Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates[J]. J Oncol, 2019, 2019:4508794. |
| [5] |
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018, 359(6382):1350-1355.
doi: 10.1126/science.aar4060 URL |
| [6] |
Coley WB . II. Contribution to the Knowledge of Sarcoma[J]. Ann Surg, 1891, 14(3):199-220.
doi: 10.1097/00000658-189112000-00015 pmid: 17859590 |
| [7] |
Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization[J]. Cell, 2018 Oct 4, 175(2):313-326.
doi: S0092-8674(18)31247-9 pmid: 30290139 |
| [8] |
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle[J]. Immunity, 2013, 39(1):1-10.
doi: 10.1016/j.immuni.2013.07.012 URL |
| [9] | Medon M, Vidacs E, Vervoort SJ, et al. HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors[J]. Cancer Res, 2017, 77(10):2594-2606. |
| [10] |
Chen R, Hou J, Newman E, et al. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin[J]. Mol Cancer Ther, 2015, 14(6):1376-1384.
doi: 10.1158/1535-7163.MCT-15-0036 URL |
| [11] |
Shindo Y, Hazama S, Maeda Y, et al. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer[J]. J Transl Med, 2014, 12:175.
doi: 10.1186/1479-5876-12-175 URL |
| [12] |
Mittica G, Capellero S, Genta S, et al. Adoptive immunotherapy against ovarian cancer[J]. J Ovarian Res, 2016, 9(1):30.
doi: 10.1186/s13048-016-0236-9 pmid: 27188274 |
| [13] |
Gao X, Mi Y, Guo N, et al. Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy[J]. Front Immunol, 2017, 8:774.
doi: 10.3389/fimmu.2017.00774 URL |
| [14] |
Patel S, Burga RA, Powell AB, et al. Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer[J]. Front Oncol, 2019, 9:196.
doi: 10.3389/fonc.2019.00196 URL |
| [15] |
Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering[J]. Nature, 2017, 545(7655):423-431.
doi: 10.1038/nature22395 URL |
| [16] |
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5):411-422.
doi: 10.1056/NEJMoa1001294 URL |
| [17] |
Klener P Jr, Otáhal P, Lateckova L, et al. Immunotherapy Approaches in Cancer Treatment[J]. Curr Pharm Biotechnol, 2015, 16(9):771-781.
doi: 10.2174/1389201016666150619114554 URL |
| [18] |
Melero I, Gaudernack G, Gerritsen W, et al. Therapeutic vaccines for cancer: an overview of clinical trials[J]. Nat Rev Clin Oncol, 2014, 11(9):509-524.
doi: 10.1038/nrclinonc.2014.111 URL |
| [19] |
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizu-mab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030):1837-1846.
doi: 10.1016/S0140-6736(16)00587-0 pmid: 26970723 |
| [20] |
Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolu-mab for Recurrent Squamous-Cell Carcinoma of the Head and Neck[J]. N Engl J Med, 2016, 375(19):1856-1867.
doi: 10.1056/NEJMoa1602252 URL |
| [21] |
Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials[J]. Ann Oncol, 2013, 24(8):2174-2180.
doi: 10.1093/annonc/mdt161 pmid: 23666915 |
| [22] |
Chiarion-Sileni V, Pigozzo J, Ascierto PA, et al. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy[J]. Br J Cancer, 2014, 110(7):1721-1726.
doi: 10.1038/bjc.2014.126 URL |
| [23] |
Calabrò L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study[J]. Lancet Respir Med, 2015, 3(4):301-309.
doi: 10.1016/S2213-2600(15)00092-2 pmid: 25819643 |
| [24] |
Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3):545-551.
doi: 10.1016/j.jhep.2016.10.029 URL |
| [25] |
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Ove-rall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma[J]. N Engl J Med, 2017, 377(14):1345-1356.
doi: 10.1056/NEJMoa1709684 URL |
| [26] |
Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain[J]. N Engl J Med, 2018, 379(8):722-730.
doi: 10.1056/NEJMoa1805453 URL |
| [27] |
He Y, Cao J, Zhao C, et al. TIM-3, a promising target for cancer immunotherapy[J]. Onco Targets Ther, 2018, 11:7005-7009.
doi: 10.2147/OTT.S170385 URL |
| [28] |
Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy[J]. Genes Cancer, 2018, 9(5-6):176-189.
doi: 10.18632/genesandcancer.180 pmid: 30603054 |
| [29] |
Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy[J]. Nat Med, 2019, 25(4):656-666.
doi: 10.1038/s41591-019-0374-x pmid: 30833750 |
| [30] |
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26):2443-2454.
doi: 10.1056/NEJMoa1200690 URL |
| [31] |
Lupo A, Alifano M, Wislez M, et al. Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer[J]. Rev Pneumol Clin, 2018, 74(5):339-350.
doi: S0761-8417(18)30215-3 pmid: 30337201 |
| [32] |
Chae YK, Pan A, Davis AA, et al. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?[J]. Clin Lung Cancer, 2016, 17(5):350-361.
doi: 10.1016/j.cllc.2016.03.011 URL |
| [33] |
Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial[J]. Lancet Oncol, 2016, 17(7):883-895.
doi: S1470-2045(16)30098-5 pmid: 27269741 |
| [34] |
Kluger HM, Zito CR, Turcu G, et al. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors[J]. Clin Cancer Res, 2017, 23(15):4270-4279.
doi: 10.1158/1078-0432.CCR-16-3146 URL |
| [35] |
Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes[J]. Clin Cancer Res, 2019, 25(15):4592-4602.
doi: 10.1158/1078-0432.CCR-18-1538 pmid: 30824587 |
| [36] |
Stovgaard ES, Dyhl-Polk A, Roslind A, et al. PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review[J]. Breast Cancer Res Treat, 2019, 174(3):571-584.
doi: 10.1007/s10549-019-05130-1 URL |
| [37] | Berland L, Heeke S, Humbert O, et al. Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors[J]. J Thorac Dis, 2019, 11(Suppl 1):S71-S80. |
| [38] |
Wang RF, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine[J]. Cell Res, 2017, 27(1):11-37.
doi: 10.1038/cr.2016.155 URL |
| [39] |
Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230):124-128.
doi: 10.1126/science.aaa1348 URL |
| [40] |
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial[J]. Lancet, 2016, 387(10031):1909-1920.
doi: 10.1016/S0140-6736(16)00561-4 pmid: 26952546 |
| [41] |
Mandal R, Chan TA. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy[J]. Cancer Discov, 2016, 6(7):703-713.
doi: 10.1158/2159-8290.CD-16-0146 URL |
| [42] |
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349):409-413.
doi: 10.1126/science.aan6733 URL |
| [43] |
Colle R, Cohen R, Cochereau D, et al. Immunotherapy and patients treated for cancer with microsatellite instability[J]. Bull Cancer, 2017, 104(1):42-51.
doi: 10.1016/j.bulcan.2016.11.006 URL |
| [44] |
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blocka-de induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014, 515(7528):568-571.
doi: 10.1038/nature13954 URL |
| [45] |
Daud AI, Loo K, Pauli ML, et al. Tumor immune profi-ling predicts response to anti-PD-1 therapy in human melanoma[J]. J Clin Invest, 2016, 126(9):3447-3452.
doi: 10.1172/JCI87324 URL |
| [46] | Krieg C, Nowicka M, Guglietta S, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy[J]. Nat Med, 2018, 24(2):144-153. |
| [47] |
Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab[J]. J Immunother Cancer, 2018, 6(1):74.
doi: 10.1186/s40425-018-0383-1 URL |
| [48] |
Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade[J]. J Clin Invest, 2018, 128(2):715-720.
doi: 10.1172/JCI96798 URL |
| [49] |
Lim SY, Lee JH, Gide TN, et al. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy[J]. Clin Cancer Res, 2019, 25(5):1557-1563.
doi: 10.1158/1078-0432.CCR-18-2795 pmid: 30409824 |
| [50] |
Felix J, Cassinat B, Porcher R, et al. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy[J]. Int Immunopharmacol, 2016, 40:466-473.
doi: 10.1016/j.intimp.2016.09.030 URL |
| [51] |
Nagato T, Ohkuri T, Ohara K, et al. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy[J]. Cancer Immunol Immunother, 2017, 66(7):877-890.
doi: 10.1007/s00262-017-1987-x URL |
| [52] |
Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]. Nature, 2018, 560(7718):382-386.
doi: 10.1038/s41586-018-0392-8 URL |
| [53] |
Li L, Zhang J, Jiang X, et al. Promising clinical application of ctDNA in evaluating immunotherapy efficacy[J]. Am J Cancer Res, 2018, 8(10):1947-1956.
pmid: 30416847 |
| [54] |
Goldberg SB, Narayan A, Kole AJ, et al. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA[J]. Clin Cancer Res, 2018, 24(8):1872-1880.
doi: 10.1158/1078-0432.CCR-17-1341 pmid: 29330207 |
| [55] |
Boeri M, Milione M, Proto C, et al. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study[J]. Clin Cancer Res, 2019, 25(7):2166-2173.
doi: 10.1158/1078-0432.CCR-18-1981 URL |
| [56] |
Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371):97-103.
doi: 10.1126/science.aan4236 pmid: 29097493 |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
